MEMPHIS, Tenn. -- Scientists at St. Jude Children's Research Hospital are investigating in adults the use of a vaccine given by nose drops that might ultimately protect children against human parainfluenza virus-type 1 (hPIV-1). This virus is the most common cause of croup, a pediatric respiratory disease that causes almost 30,000 hospitalizations each
year and many more emergency room visits. These findings were published in the current issue of Vaccine.
Successful development of an effective hPIV-1 vaccine would be significant
because none is currently available and a vaccine that is given to infants
using nose drops would eliminate the discomfort and complications of
injections.
Because the vaccine contains a live virus, it should stimulate both
antibody and cellular immune responses, which together may provide durable
protection from hPIV-1. In cellular immunity, special cells, rather than
antibodies, destroy virus-infected cells inside the body.
The vaccine consists of Sendai virus (SeV), a mouse virus that is similar
enough to hPIV-1 to act as a vaccine, but different enough to have never been
associated with a human disease, according to Karen Slobod, MD, associate
member of the department of Infectious Diseases. Slobod is the lead author of the Vaccine report.
Pre-clinical studies by the St. Jude team proved that intranasal SeV
vaccine can protect against the human croup virus. The results of the study in
nine healthy adults demonstrated that the SeV vaccine was safe and well
tolerated. None of those vaccinated experienced any significant reactions,
such as respiratory symptoms or laboratory abnormalities.
This FDA-approved Phase I trial was initiated in adults as a first step,
prior to future testing in children and then infants-the ultimate target
population, said Jerry Shenep, MD, member of the department of Infectious
Diseases and a co-author of the paper.
"The St. Jude team based the vaccine on SeV for two reasons," said Allen
Portner, PhD, member of the department of Infectious Diseases and a co-
author of the paper. "First, it appears likely that this virus will provide
immunity against hPIV-1 in infants. Second, despite the fact that children
frequently have close contact with mice carrying SeV, there has never been a
confirmed case of SeV infection in humans."
Using a natural mimic of a human virus follows in the tradition of the
world's most successful vaccine, the smallpox vaccine, said Julia Hurwitz,
PhD, a member of the department of Immunology.
"The smallpox vaccine was based on the cowpox virus, which caused only
limited skin infection in healthy humans," Hurwitz said. "Yet it provided
lifelong protection against smallpox and eradicated this disease from the
human population in the 1970s. We hope that SeV will similarly help eradicate
hPIV-1 as a cause of childhood croup."
Other authors of the study are Jorge Lujan-Zilbermann, Kim Allison, Brita
Brown, Ruth Ann Scroggs and Chris Coleclough.
This work was support in part by NIH and ALSAC.
Source: St. Jude Children's Research Hospital
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.